{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T23:56:20Z","timestamp":1771977380498,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Advanced Accelerator Applications, a Novartis company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s41669-021-00280-9","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T08:03:56Z","timestamp":1626249836000},"page":"715-725","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Estimation of Health-Related Utilities for 177Lu-DOTATATE in GEP-NET Patients Using Utilities Mapped from EORTC QLQ-C30 to EQ-5D-3L and QLU-C10D Utilities"],"prefix":"10.1007","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3391-1551","authenticated-orcid":false,"given":"Ioana-Alexandra","family":"Soare","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Leeuwenkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Longworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"issue":"1","key":"280_CR1","first-page":"29","volume":"26","author":"M D\u00edez","year":"2013","unstructured":"D\u00edez M, Teul\u00e9 A, Salazar R. Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment. Ann Gastroenterol. 2013;26(1):29.","journal-title":"Ann Gastroenterol"},{"issue":"10","key":"280_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335\u201342.","journal-title":"JAMA Oncol"},{"key":"280_CR3","doi-asserted-by":"crossref","unstructured":"Genus T, et al. Incidence and prevalence of neuroendocrine tumours in England. In: UKI NETS 15th national conference. BioScientifica. 2017.","DOI":"10.1530\/endoabs.52.OC3"},{"issue":"2","key":"280_CR4","first-page":"29","volume":"7","author":"A Oladejo","year":"2009","unstructured":"Oladejo A. Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)-approach to diagnosis and management. Ann Ibadan Postgrad Med. 2009;7(2):29\u201333.","journal-title":"Ann Ibadan Postgrad Med"},{"issue":"3","key":"280_CR5","doi-asserted-by":"publisher","first-page":"R153","DOI":"10.1530\/ERC-13-0125","volume":"21","author":"M Fraenkel","year":"2014","unstructured":"Fraenkel M, et al. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer. 2014;21(3):R153\u201363.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"280_CR6","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1186\/s12885-018-5057-3","volume":"18","author":"R Basuroy","year":"2018","unstructured":"Basuroy R, et al. Delays and routes to diagnosis of neuroendocrine tumours. BMC Cancer. 2018;18(1):1122.","journal-title":"BMC Cancer"},{"issue":"2","key":"280_CR7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.5114\/aoms.2017.65449","volume":"13","author":"S Yalcin","year":"2017","unstructured":"Yalcin S, et al. Gastroenteropancreatic neuroendocrine tumors: recommendations of Turkish multidisciplinary neuroendocrine tumor study group on diagnosis, treatment and follow-up. Arch Med Sci AMS. 2017;13(2):271.","journal-title":"Arch Med Sci AMS"},{"issue":"4","key":"280_CR8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.clon.2011.08.006","volume":"24","author":"KE \u00d6berg","year":"2012","unstructured":"\u00d6berg KE. The management of neuroendocrine tumours: current and future medical therapy options. Clin Oncol. 2012;24(4):282\u201393.","journal-title":"Clin Oncol"},{"issue":"3","key":"280_CR9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/ph12030114","volume":"12","author":"U Hennrich","year":"2019","unstructured":"Hennrich U, Kopka K. Lutathera\u00ae: the First FDA-and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals. 2019;12(3):114.","journal-title":"Pharmaceuticals"},{"issue":"2","key":"280_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med"},{"issue":"16","key":"280_CR11","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander T, et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0, Tyr3] octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23(16):4617\u201324.","journal-title":"Clin Cancer Res"},{"issue":"25","key":"280_CR12","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","volume":"36","author":"J Strosberg","year":"2018","unstructured":"Strosberg J, et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-dotatate in the phase III NETTER-1 trial. J Clin Oncol. 2018;36(25):2578.","journal-title":"J Clin Oncol"},{"key":"280_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jcpo.2016.09.005","volume":"11","author":"NJ Devlin","year":"2017","unstructured":"Devlin NJ, Lorgelly PK. QALYs as a measure of value in cancer. J Cancer Policy. 2017;11:19\u201325.","journal-title":"J Cancer Policy"},{"issue":"2","key":"280_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40258-017-0310-5","volume":"15","author":"NJ Devlin","year":"2017","unstructured":"Devlin NJ, Brooks R. EQ-5D and the EuroQol group: past, present and future. Appl Health Econ Health Policy. 2017;15(2):127\u201337.","journal-title":"Appl Health Econ Health Policy"},{"key":"280_CR15","unstructured":"Longworth L, Rowen D. NICE DSU technical support document 10: the use of mapping methods to estimate health state utility values.  2011. Available from http:\/\/www.nicedsu.org.uk."},{"issue":"5","key":"280_CR16","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. JNCI J Natl Cancer Inst. 1993;85(5):365\u201376.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"2","key":"280_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/hec.1580","volume":"19","author":"J Brazier","year":"2010","unstructured":"Brazier J, Tsuchiya A. Preference-based condition-specific measures of health: what happens to cross programme comparability? Health Econ. 2010;19(2):125\u20139.","journal-title":"Health Econ"},{"issue":"3","key":"280_CR18","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jval.2011.12.003","volume":"15","author":"MM Versteegh","year":"2012","unstructured":"Versteegh MM, et al. Condition-specific preference-based measures: benefit or burden? Value Health. 2012;15(3):504\u201313.","journal-title":"Value Health"},{"key":"280_CR19","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s10198-020-01195-8","volume":"21","author":"M Kennedy-Martin","year":"2020","unstructured":"Kennedy-Martin M, et al. Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. Eur J Health Econ. 2020;21:1245\u201357.","journal-title":"Eur J Health Econ."},{"issue":"1","key":"280_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1359-6349(12)70023-X","volume":"10","author":"G Velikova","year":"2012","unstructured":"Velikova G, et al. Health-related quality of life in EORTC clinical trials\u201430 years of progress from methodological developments to making a real impact on oncology practice. Eur J Cancer Suppl. 2012;10(1):141\u20139.","journal-title":"Eur J Cancer Suppl"},{"issue":"3","key":"280_CR21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s11136-015-1217-y","volume":"25","author":"M King","year":"2016","unstructured":"King M, et al. QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30. Qual Life Res. 2016;25(3):625\u201336.","journal-title":"Qual Life Res"},{"issue":"12","key":"280_CR22","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/hec.3950","volume":"28","author":"R Norman","year":"2019","unstructured":"Norman R, et al. UK utility weights for the EORTC QLU-C10D. Health Econ. 2019;28(12):1385\u2013401.","journal-title":"Health Econ"},{"issue":"9","key":"280_CR23","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.2967\/jnumed.111.087932","volume":"52","author":"S Khan","year":"2011","unstructured":"Khan S, et al. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0, Tyr3] octreotate. J Nucl Med. 2011;52(9):1361\u20138.","journal-title":"J Nucl Med"},{"issue":"4","key":"280_CR24","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s11136-015-1116-2","volume":"25","author":"B Doble","year":"2016","unstructured":"Doble B, Lorgelly P. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms. Qual Life Res. 2016;25(4):891\u2013911.","journal-title":"Qual Life Res"},{"issue":"4","key":"280_CR25","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1177\/0272989X11427761","volume":"32","author":"MM Versteegh","year":"2012","unstructured":"Versteegh MM, et al. Mapping Qlq-C30, Haq, and Msis-29 on Eq-5d. Med Decis Mak. 2012;32(4):554\u201368.","journal-title":"Med Decis Mak"},{"issue":"9","key":"280_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta18090","volume":"18","author":"L Longworth","year":"2014","unstructured":"Longworth L, et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technol Assess. 2014;18(9):1\u2013224.","journal-title":"Health Technol Assess."},{"issue":"2","key":"280_CR27","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40273-017-0582-5","volume":"36","author":"MT King","year":"2018","unstructured":"King MT, et al. Australian utility weights for the EORTC QLU-C10D, a multi-attribute utility instrument derived from the cancer-specific quality of life questionnaire, EORTC QLQ-C30. Pharmacoeconomics. 2018;36(2):225\u201338.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"280_CR28","first-page":"125","volume":"23","author":"AP Brogan","year":"2017","unstructured":"Brogan AP, et al. Payer perspectives on patient-reported outcomes in health care decision making: oncology examples. J Manag Care Spec Pharm. 2017;23(2):125\u201334.","journal-title":"J Manag Care Spec Pharm"},{"issue":"20","key":"280_CR29","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.12998\/wjcc.v8.i20.4793","volume":"8","author":"J Palmer","year":"2020","unstructured":"Palmer J, Leeuwenkamp OR. Cost-effectiveness of lutetium (177Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden. World J Clin Cases. 2020;8(20):4793.","journal-title":"World J Clin Cases"},{"issue":"12","key":"280_CR30","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1080\/13696998.2020.1830286","volume":"23","author":"O Leeuwenkamp","year":"2020","unstructured":"Leeuwenkamp O, et al. Cost-effectiveness of Lutetium [177Lu] oxodotreotide versus best supportive care with octreotide in patients with midgut neuroendocrine tumors in France. J Med Econ. 2020;23(12):1534\u201341.","journal-title":"J Med Econ."},{"issue":"2","key":"280_CR31","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/bjc.2012.560","volume":"108","author":"G Yadegarfar","year":"2013","unstructured":"Yadegarfar G, et al. Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. Br J Cancer. 2013;108(2):301\u201310.","journal-title":"Br J Cancer"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-021-00280-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-021-00280-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-021-00280-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T07:41:57Z","timestamp":1637653317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-021-00280-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["280"],"URL":"https:\/\/doi.org\/10.1007\/s41669-021-00280-9","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,14]]},"assertion":[{"value":"5 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PHMR received financial support from Advanced Accelerator Application, a Novartis company, for conducting the study, including data analysis and preparation of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"A. Soare, and Dr L. Longworth are full-time employees at PHMR. PHMR received financial support from Advanced Accelerator Application, a Novartis company, for the work, including data analysis and preparation of the manuscript. Oscar Leeuwenkamp is a full-time employee of Advanced Accelerator Application, a Novartis company, which funded the work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable (reanalysis of existing datasets based on studies that have previously received ethical approvals).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable (reanalysis of existing datasets based on studies that have previously received ethical approvals).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not available.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material (data transparency)"}},{"value":"Not available.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability (software application or custom code)"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AS: led the drafting of the manuscript, contributed to the analysis, study design and interpretation. OL: contributed to the study design, interpretation and drafting of the manuscript. LL: led the study design and interpretation, contributed to the analysis and drafting of the manuscript. Oversight of the project.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}